hVIVO plc (AIM:HVO)

Market Cap	73.82M
Revenue (ttm)	66.22M
Net Income (ttm)	10.65M
Shares Out	680.37M
EPS (ttm)	0.02
PE Ratio	7.00
Forward PE	n/a
Dividend	0.00 (1.84%)
Ex-Dividend Date	May 15, 2025

Volume	3,112,799
Average Volume	2,395,566
Open	10.34
Previous Close	10.25
Day's Range	10.00 - 11.50
52-Week Range	6.50 - 30.45
Beta	1.07
RSI	59.27
Earnings Date	Sep 10, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Yamin Khan
• Employees: 301
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HVO

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.